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Abbreviations used 
AT1 angiotensin II type 1 receptor 
anti-GBM GN anti-glomerular basement membrane glomerulonephritis 
Col1a1 collagen-1-alpha-1 
FSGS focal and segmental glomerulosclerosis 
GFR glomerular filtration rate 
JMC juxtamedullary cortex 
MMP matrix metalloprotease  
SHR spontaneously hypertensive rats 
TTA tetradecylthioacetic acid 
TIMP tissue inhibitor of metalloprotease 
2K1C two kidney one clip 
WKY Wistar Kyoto rats 
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1. Introduction 
1.1 Why is it important to study chronic renal failure? 
When we wrote the first application for the thesis grant in 2004, the annual incidence 
of end-stage renal disease in Norway was 92,3 per million and the prevalence 641,4 
per million. Incidence and prevalence have increased continuously since the start of 
registration in 1980, and the newest numbers from 2009 are 116 per million for 
annual incidence and 843 per million for prevalence1 (Figure 1). 
Figure 1:  New patients in renal replacement therapy in Norway from 1980 - 20091  
 
As the Norwegian population is expected to become older and more obese, the 
prevalence of renal risk factors are expected to increase, resulting in higher incidence 
and prevalence of end stage renal disease during the next decades.2 Apart from the 
physical and psychological stress for the patient, the economic burdens of renal 
replacement therapy for the health care systems are huge. Considerable efforts have 
been undertaken to understand how and why chronic kidney failure develops, and to 
find drugs that prevent or slow-down this process. However, our understanding of 
renal disease progression is still limited in the majority of cases.  
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1.2 Common final pathway to end stage renal disease 
Despite different underlying diseases, the degenerating process in the kidney seems to 
follow a similar morphological pattern, often referred to as the common final pathway 
of renal disease progression. The morphological hallmarks of this pathway are 
segmental and global glomerulosclerosis, tubular atrophy, and interstitial fibrosis 
(Figure 2).3 
 
Figure 2: Morphological hallmarks of renal disease progression. Three different diseases 
(from left to right membranous nephropathy, crescentic glomerulonephritis, focal and 
segmental glomerulosclerosis) show uniform changes: segmental sclerosis, tubular atrophy, 
and interstitial fibrosis. Scale bar 100 μm, periodic acid Schiff stain. 
1.2.1 Pathogenesis of segmental sclerosis 
The pathogenesis of segmental sclerosis is extensively described by Kriz in a series of 
papers in the 1990s.4-8 The initial event in the development of segmental sclerosis is 
thought to be damage to the glomerular epithelial cell, the podocyte.9 Damage may be 
caused by different agents (toxic, hemodynamic, inflammatory and immune-
mediated). Damaged podocytes detach from the glomerular basement membrane, 
leaving bare areas. Capillary wall sections denuded of podocytes tend to become 
adherent to the Bowman’s capsule. Segmental sclerosis develops from this adhesion 
through several processes, often occurring simultaneously: 
• Damage spreads to neighbouring podocytes, initiating the described events 
repeatedly.  
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• Still open and perfused capillaries in an adhesion will have ongoing filtration. 
The filtrate is now directed to the Bowman’s capsule and the interstitium 
behind, forming a paraglomerular space and enlarging the adherence.  
• Capillaries close to the adherence become narrowed by hyaline lesions or 
thrombosis, and eventually obliterate. 
• Cells disappear from the area and extracellular matrix increases. 
A well-developed lesion of segmental sclerosis commonly shows obliteration of the 
capillary tuft, increased extracellular matrix and adherence with the Bowman’s 
capsule. Usually, there is podocyte hypertrophy; often, absorption droplets and 
pseudocysts (syn. cytoplasmic vacuoles) are seen. Hyalinosis and endocapillary foam 
cells might be present. Electron microscopy shows variable podocyte foot process 
effacement, typically accompanied by prominent cytoskeleton along the glomerular 
basement membrane, increase of cellular organelles, and some degree of microvillous 
transformation.10 
This glomerular lesion is morphologically well defined but entirely unspecific. It 
includes both primary (idiopathic) and secondary forms with known aetiology. The 
term used is focal and segmental glomerulosclerosis (FSGS). However, when FSGS is 
investigated in serial sections, it is often diffuse (present in more than 50% of 
glomeruli),11, 12 and in advanced cases, FSGS is no longer segmental either. 
Secondary FSGS includes diverse diseases such as hereditary forms, drug associated 
diseases, viral infections, and glomerular scarring in various forms of chronic 
glomerulonephritis.  
Finally, and most important in the context of the present thesis, secondary FSGS 
might develop as a consequence of altered glomerular hemodynamics with 
hyperperfusion and increased glomerular pressure in conditions like hypertension, 
obesity, diabetes, and considerable nephron loss due to any advanced renal disease. It 
is generally accepted that the common final pathway to end stage renal disease is 
based on this mechanism, also called the overload hypothesis. The hypothesis was 
first described 1981 in a milestone paper by Hostetter, Brenner et al13 studying the 
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remaining rat kidney after subtotal renal ablation. Substantial loss of kidney tissue 
leads to compensatory increase of single nephron glomerular filtration rate in the 
remaining glomeruli. To increase glomerular filtration rate, glomerular plasma flow 
and glomerular pressure have to be elevated. Altered hemodynamics give rise to 
podocyte changes: podocytes show absorption droplets, pseudocysts, effacement of 
foot processes, and microvillous transformation. As a consequence of glomerular 
hypertension, focal and segmental glomerulosclerosis develops, increases, and 
eventually proceeds to global glomerulosclerosis, leading to further nephron loss and 
continuing in a vicious circle. 
1.3 Pathways from glomerular disease to tubular atrophy 
It is still not well understood how the glomerular process is transmitted to tubules and 
interstitium, but several hypotheses have been put forward.  
1.3.1 Proteinuria hypothesis 
In proteinuric glomerular diseases tubules are chronically damaged by uptake of 
filtered protein.14 
The filtration barrier is damaged in most glomerular diseases.  Proteins that usually 
are not filtered then appear in the primary filtrate. These proteins are reabsorbed by 
the proximal tubules and degraded in lysosomes. The capacity for lysosomal protein 
degradation is limited. Lysosomes will eventually rupture and expose tubular cells to 
lysosomal enzymes. This triggers an inflammatory reaction with upregulation of 
inflammatory and vasoactive genes, finally leading to interstitial fibrosis and tubular 
atrophy.14   
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1.3.2 Misdirected filtration hypothesis 
Misdirected filtration in areas of segmental glomerulosclerosis towards the 
Bowman’s capsule, along the capsule to the tubular outlet, and downstream along 
the proximal tubule causes tubular atrophy.15 
Areas with segmental sclerosis often contain open 
capillary loops. These capillaries are still perfused 
but miss the most important part of the filtration 
barrier, the podocyte. The capillaries filter, but the 
composition of the primary filtrate is changed, and 
the primary filtrate does not reach the Bowman’s 
room but is led to a paraglomerular space. Ongoing 
filtration will expand this space and extend it further 
along the Bowman’s capsule via the tubular origin to 
the proximal tubule. From there, the misdirected 
filtrate spreads downstream along the course of the 
proximal tubule, expanding the space between the 
tubular cells and the tubular basement membrane, 
eventually leading to tubular degeneration (Figure 
3).16, 17 
1.3.3 Hypoxia hypothesis 
Impairment of blood flow to the tubulointerstitial compartment causes ischemic 
damage of the tubules. Chronic ischemia leads to tubular atrophy and interstitial 
fibrosis. 18 
The vascular organisation of the kidney is exceptional as two capillary beds are 
connected in series. There are only two other systems in the human body that include 
two successive capillary beds: the hypophyseal portal system connecting 
hypothalamus and pituary, and the hepatic portal system connecting the capillary 
plexus in the intestine via the vena portae with the sinusoids in the liver. The first 
 
Figure 3: Schematic 
drawing to illustrate the 
misfiltration hypothesis. 
There is a misdirected 
filtrate from the area of 
segmental sclerosis along 
the Bowman’s capsule to 
the proximal tubule (red 
arrow).  
 12 
capillary bed in the kidney is the glomerulus supplied by the afferent arteriole. The 
efferent arteriole connects the glomerulus 
to the second capillary bed, the peritubular 
capillaries, providing the tubules with 
oxygen and nutrients. Blood flow 
impairment to the tubulointerstitial 
compartment could occur through several 
mechanisms: constriction of the afferent 
arteriole, obliteration of the glomerular 
capillaries, for example through segmental 
sclerosis, or loss of peritubular capillaries 
(Figure 4).19, 20 Hypoxia has been shown to 
be associated with upregulation of pro-
inflammatory and pro-fibrotic mediators, 
and this would cause tubular atrophy and interstitial fibrosis. When fibrosis develops, 
extension of the diffusion distance from the capillaries to the tubules cell will further 
diminish oxygen supply. 
1.4 Treatment options 
1.4.1 Angiotensin receptor blockers 
The introduction of drugs interfering with the renin angiotensin system has been a 
breakthrough in the treatment of renal diseases. The stabilisation of the previously 
strongly increasing incidence rate of end stage renal disease in the USA during the 
last 5-10 years has been at least partially ascribed to the introduction of these drugs. 
 
Figure 4: Schematic drawing to 
illustrate the hypoxia hypothesis. Due to 
segmental sclerosis there is reduced 
outflow from the glomerulus and 
hypoperfusion of the peritubular 
capillaries. Tubular segments from 
several nephrons develop atrophy. 
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Figure 5: Chemical structure of candesartan 21 
 
Angiotensin receptor blockers (examples include losartan and candesartan, Figure 5) 
inhibit the effects of the renin angiotensin system by blocking its angiotensin II type 1 
(AT1) receptor, and the angiotensin convertase inhibitors (for example captopril and 
enalapril) by reducing the production of angiotensin II. The renoprotective effects of 
these drugs are based on their ability to reduce systemic blood pressure, to normalize 
glomerular pressure by dilatation of the efferent arteriole22, and to inhibit the non-
hemodynamic profibrotic effects of angiotensin II.23 
However Angiotensin converting enzyme inhibitors or AT1 receptor blockers are 
mostly not capable to halt or even reverse the atrophy process, and other treatment 
options are badly needed. 
In this thesis we have focused on 2 novel drugs that could have renoprotective effects.  
1.4.2 Tetradecylthioacetic acid TTA 
Tetradecylthioacetic acid (TTA) is a saturated straight-chain thia fatty acid with a 
backbone of 14 carbon atoms and a sulfur atom inserted into the 3-position (Figure 6). 
 
Figure 6: Chemical structure of tetradecylthioacetic acid (TTA) 24, 25 
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TTA increases both cellular uptake and oxidation of fatty acids by proliferation of 
mitochondria. These effects are partly ascribed to activation of PPAR alpha by TTA. 
TTA can thus decrease free fatty acid content in the serum and change the serum 
composition of fatty acids. Decreased free fatty acid concentration in the serum 
facilitates glucose uptake in muscle and adipose tissues, and has thus a beneficial 
effect on insulin sensitivity.26, 27 Hypertension is both a component of chronic renal 
disease and metabolic syndrome, and alteration of lipid profiles in the serum has an 
impact on blood pressure levels.28, 29 In addition, dyslipidemia worsens renal 
insufficiency.30 Other PPAR agonists interact with the renin angiotensin system, and 
this could also have a blood-pressure reducing effect.31 We therefore hypothesised 
that TTA might reduce hypertension and morphological damage in chronic 
hypertensive kidney disease. 
1.4.3 Pirfenidone 
Tubular atrophy and interstitial fibrosis in advanced renal disease are well correlated 
with kidney function measured by serum creatinine.32, 33 Antifibrotic drugs might 
therefore have a renoprotective potential. 
Pirfenidone is a new antifibrotic drug (Figure 7). The antifibrotic effect of pirfenidone 
was first described in bleomycin induced lung fibrosis in the hamster.34 Subsequently, 
the drug was tested in animal models of fibrosis in different organs.35-43  
 
 
 
Figure 7: Chemical structure of pirfenidone44 
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Pirfenidone has been tested in several models of kidney disease: anti-Thy-1 
glomerulonephritis,45 unilateral ureteral obstruction,46 subtotal nephrectomy,47 
streptozotocin diabetes,48 cyclosporine toxicity,49 vanadate50 and doxorubicin induced 
kidney fibrosis.51 These studies confirmed the antifibrotic effect of pirfenidone in 
various kidney diseases, but its mechanism of action is not well understood. It has 
however been shown that pirfenidone reduces transforming growth factor beta 
production and that this is associated with reduced collagen production.52 
Furthermore, pirfenidone decreases oxidative stress51, 52 and has anti-inflammatory 
properties.53-55  
 16 
2. Aims of the thesis 
To study the pathogenesis of chronic glomerular damage, tubular atrophy, and 
interstitial fibrosis in a rat model of hypertensive renal damage. 
- to describe the morphological changes 
- to understand the development of interstitial fibrosis 
- to test common hypotheses regarding development of tubular atrophy 
To study the effect of potential renoprotective drugs in a rat model of hypertensive 
renal damage and in a rat model of chronic glomerulonephritis. 
- Tetradecylthioacetic acid in two kidney one clip (2K1C) hypertension 
- Pirfenidone in anti-glomerular basement membrane glomerulonephritis (anti-
GBM GN)  
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3. Material and methods 
This chapter contains only methods that are not described in detail in the material and 
methods sections of the respective papers.   
3.1 Experimental models 
3.1.1 Spontaneously hypertensive rats (SHR) 
The spontaneously hypertensive rat was developed by inbreeding of Wistar Kyoto rats 
with high blood pressure 56, 57 and is now one of the most studied animal models for 
genetic hypertension.58  
Measured by a vascular cast model, the lumen diameter of the afferent arteriole in 
SHR is reduced compared to Wistar Kyoto rats (WKY), and this is so already in the 
prehypertensive state.59, 60 Reduced lumen diameter is not caused by media 
hypertrophy in young SHR.61 Reduced lumen diameter increases the vascular 
resistance in the kidney and in order to maintain renal blood flow and glomerular 
filtration rate, arterial pressure has to be raised. Reduced lumen diameter may thus 
contribute to development of systemic hypertension in this rat strain.62  
Glomerular capillary pressure increases with age in the juxtamedullary cortex (JMC) 
accompanied by increased glomerular tuft diameter.63 Increased glomerular capillary 
pressure is considered an important mechanism for development of segmental 
glomerulosclerosis.13 Chronic glomerular and tubulointerstitial damage starts in the 
JMC, is present from about 40 weeks of age, and increases with higher age.63, 64 
An overview of physiological and morphological parameters is shown in figure 8. 
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Figure 8: Hemodynamic and morphological parameters in WKY (blue) and SHR (red) at 
various ages65 
3.1.2 Two-kidney one-clip hypertension (2K1C) 
The model was first described by Goldblatt in 1934, who induced hypertension in 
dogs by constricting the renal arteries.66 
A clip around the left renal artery causes reduced perfusion of the left kidney (Figure 
9) inducing increased renin secretion. Thereafter, the angiotensin II level rises, and 
mainly due to its vasoconstrictory effect blood pressure increases rapidly.67 The non-
clipped kidney is exposed to elevated blood pressure, and morphological signs of 
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hypertensive damage develop about 20 weeks after clipping. In paper IV, we studied 
the kidney 24 weeks after surgery when damage was well established. 
 
3.1.3 Anti-GBM GN 
Rabbits were sensitised by a purified preparation from glomerular basement 
membranes from rats. Samples of venous blood were taken from rabbits every 3-4 
weeks. Serum was separated by centrifugation and stored. Glomerulonephritis was 
induced by a single dose of pooled serum intravenously.68 Rabbit anti-GBM 
antibodies bind to glomerular basement membranes (heterologous phase). 
Subsequently, rat antibodies react with rabbit antibodies fixed to the basement 
membrane (autologous phase). A glomerulonephritis develops with necrosis and 
Figure 9: 2K1C hypertension. A clip around the left 
renal artery leads to reduced perfusion of the left 
kidney and to compensatory hypertrophy of the 
right kidney. 
Figure 10: Schematic drawing to show the sensitisation of rabbits by a purified suspension of 
glomerular basement membranes from rats. Rabbit serum is so injected in rats and induces a 
crescentic GN. 
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crescents in the acute phase and segmental sclerosis, tubular atrophy and interstitial 
fibrosis in the chronic phase (Figure 10). 
3.2 Collagen quantification with Sirius Red stain 
Sirius Red stain is specific for collagens.69, 70 The natural birefringence of interstitial 
collagens is enhanced by Sirius Red and makes the stain particularly suitable for 
quantification by image analysis. The amount of birefringence is dependent on 
staining conditions and section thickness.71 The use of tissue macroarray paraffin 
blocks containing kidney tissue from all rats, ensured minimal variation regarding 
section thickness and staining quality (Figure 11).  
 
 
Sections with five μm thickness were stained in 1% Sirius Red F3B in a saturated 
solution of picric acid for one hour, rapidly dehydrated in graded alcohols, cleared, 
and mounted. The sections were investigated under polarized light in a Leica DMLB 
microscope connected to a CCD ColorView IIIu camera. For image acquisition 
Olympus DP-soft 5.0 software was used. Colour images from outer cortex and JMC 
were obtained by taking consecutive samples parallel to the kidney capsule and to the 
corticomedullary border. Seven images from outer and five images from 
juxtamedullary cortex were analysed per rat. Images were acquired with a 20x 
Figure 11: tissue macroarray block (left) and section stained with Sirius Red (centre). The 
label (right) identifies the coded tissue pieces. + designates a piece of liver tissue for 
proper orientation. 
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objective under constant identical illumination and polarisation settings. An online 
shading correction was performed. An image resolution of 480 x 480 pixels was 
chosen, corresponding to an area of 477 x 477 μm and a resolution of 0,99 μm2/pixel. 
Images were stored as TIFF (tagged image file format). For automatic image analysis 
analySISD 5.0 software was used. The HSI (hue, saturation, intensity) colour space 
was used, and the image was separated into the hue component resulting in a 256 grey 
scale image. Lower and upper thresholds for recognition of birefringent collagen were 
set on the grey scale image. The same thresholds were used for all images. Collagen 
content was expressed as per cent detected area. The investigation was done blindly 
on coded sections (Figure 12). 
 
Figure 12: JMC of SHR with one artery (arrow) and two glomeruli (*). The left image is 
taken under polarized light. The image in the centre is a grey scale image after separation 
with the hue component. The image to the right shows the detected area (red) after 
setting an appropriate threshold. Scale bar 100 μm, Sirius red stain. 
* 
* 
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5. Main results 
The first three papers describe chronic hypertensive nephropathy in a rat model of 
genetic hypertension, the spontaneously hypertensive rat (SHR). The papers describe 
the pattern of kidney damage, mechanisms behind interstitial fibrosis, and conclude in 
the end that tubular atrophy is caused by reduced urinary flow induced by afferent 
arteriolopathy and glomerular collapse.   
Paper IV and V describe the effect of treatment in two different rat models, the 
chronic 2K1C hypertensive rat, and a rat model of chronic glomerulonephritis. Both 
models develop kidney damage in a considerable shorter time than SHR and are 
suitable for testing the effect of renoprotective drugs.  
5.1 Paper I 
Glomerular charge selectivity is impaired in hypertensive nephropathy. 
The study investigated the mechanism of proteinuria and described the associated 
morphological changes in 80-week-old SHR. A disturbance of the glomerular 
filtration barrier with loss of negative charges in the JMC was demonstrated by the 
increased sieving coefficient of anionic chymotrypsinogen compared to the sieving 
coefficient of neutral chymotrypsinogen and compared to WKY. Morphological 
parameters of a distorted glomerular filter were absorption droplets in podocytes and 
effacement of foot processes, while podocyte pseudocysts indicated more advanced 
podocyte damage. In the JMC of SHR an increased number of glomeruli with 
absorption droplets in podocytes was found by light microscopy and effacement of 
foot processes as well as pseudocysts demonstrated by electron microscopy. 
Adherences of the glomerular tuft to Bowman’s capsule, a consequence of podocyte 
damage, were abundant. Glomerular changes were accompanied by increased 
tubulointerstitial damage in the JMC of SHR. 
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5.2 Paper II 
Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-
N-peptidase in hypertension-induced renal damage. 
The pattern of interstitial fibrosis and some of the mechanisms behind collagen 
deposition were investigated in 60-week-old spontaneously hypertensive rats. 
Both vascular, glomerular and tubulointerstitial changes were mainly present in the 
JMC of SHR.  Arteries and arterioles showed muscular wall hypertrophy and intima 
thickening. There were glomerular collapse and glomerular segmental sclerosis. 
Tubular atrophy and interstitial fibrosis were still focal. Quantification of collagen 
with Sirius red stain and image analysis showed significantly increased amount in the 
JMC of SHR compared with outer cortex of SHR and compared with JMC of the 
control group WKY.  
Increased collagen deposition was a consequence of increased collagen production as 
shown by increased mRNA expression for collagen-1-alpha-1 (col1a1) and for 
procollagen-n-peptidase. Collagen content was further modified by disturbed collagen 
metabolism.  mRNA expression of the collagen digesting proteins matrix 
metalloprotease (MMP) 2 and 9 and the tissue inhibitors of metalloproteases (TIMP) 
1 and 2 were increased in SHR compared to WKY.  TIMP-1 followed closely the 
expression pattern of col1a1 at the mRNA and protein level and might therefore be of 
particular importance. Interstitial fibrosis in SHR is thus a consequence of increased 
collagen production, increased collagen deposition and disturbed collagen breakdown. 
 
5.3 Paper III 
Afferent arteriolopathy and glomerular collapse but not segmental sclerosis 
induce tubular atrophy in old spontaneously hypertensive rats. 
The relationship between morphological changes of afferent arteriole, glomerulus and 
proximal tubule were studied in 60-week-old SHR by serial sections. 
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Only nephrons with glomerular collapse showed both tubular atrophy and an 
increased wall hypertrophy of the afferent arteriole. Nephrons with glomerular 
segmental sclerosis did not show tubular atrophy. Afferent arteriolar diameter 
negatively correlated with glomerular capillary volume fraction and tubular diameter, 
implying reduced glomerular and tubular flow. Tubular cells are ciliated. Bending of 
cilia by urine flow induces an increase of inversin positivity in tubular cells. 
Degenerating and atrophic tubules showed reduced inversin positivity indicating 
changed ciliary signalling due to reduced urinary flow. We concluded that nephron 
loss in SHR is initiated by afferent arteriolopathy, leading to glomerular collapse and 
reduced urinary flow with subsequent tubular atrophy.  
5.4 Paper IV 
Prevention of hypertension and organ damage in 2-kidney 1-clip rats by 
tetradecylthioacetic acid. 
Dietary lipids affect blood pressure. 2K1C hypertensive rats were treated with the 
modified fatty acid tetradecylthioacetic acid (TTA). TTA reduced blood pressure both 
when given immediately after clipping and when treatment started with a delay of five 
weeks. There was no proteinuria in treated animals six months after clipping. Kidney 
damage, measured by podocyte changes, segmental and global glomerulosclerosis, 
and a tubulointerstitial damage score, was greatly reduced.  
The effect of TTA is explained by interference with the renin angiotensin system, 
which we confirmed by showing that renin production in the clipped kidney was 
decreased, and that plasma renin activity and angiotensinogen production in the 
adipose tissue were reduced. Furthermore, TTA altered the composition of serum 
fatty acids, resulting in an increase of oleic acid, which has a blood pressure lowering 
effect. Finally, the urinary excretion of the potent vasoconstrictor 8-iso-prostaglandin 
F2 was reduced. Kidney damage in this study thus seemed to be prevented mainly by 
the blood pressure lowering effects of TTA. 
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5.5 Paper V 
Pirfenidone and candesartan ameliorate morphologic damage in mild chronic 
anti-GBM nephritis in rats. 
The renoprotective effect of inhibitors of the renin angiotensin system is well known. 
Pirfenidone is a new drug with antifibrotic properties. The effect of pirfenidone was 
compared to the angiotensin II type I receptor antagonist candesartan, and a 
combination of both drugs was tested in chronic anti-GBM GN. Absorption droplets 
in podocytes indicated a defect in the filtration barrier, and the percentage of 
glomeruli with absorption droplets was well correlated with the amount of 
proteinuria. Both pirfenidone and candesartan reduced the number of glomeruli with 
absorption droplets in podocytes and decreased proteinuria. Tubular degeneration and 
cortical col1a1 expression were reduced by both drugs. There was no difference 
regarding the various parameters between pirfenidone and candesartan, underlining 
the renoprotective potential of pirfenidone. The more consistent pattern of beneficial 
effects on morphological damage shown by candesartan treatment however suggested 
a slightly better beneficial effect. Combination therapy was superior to candesartan 
monotherapy regarding reduction of blood pressure after 3 weeks as well as reduction 
of percentage glomeruli with absorption droplets. 
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6. General discussion 
In the first part, the morphological damage pattern in the JMC of SHR is discussed, 
and it will be argued that tubular atrophy is a consequence of reduced flow due to 
glomerular hypoperfusion and hypertrophy of the afferent arteriole. 
The second part discusses the renoprotective effects of TTA, candesartan and 
pirfenidone. 
6.1 Overload in the JMC of SHR 
Papers I – III studied pathogenetic aspects of nephron loss in a rat model of chronic 
hypertension, commonly accepted as a model for essential hypertension in man. The 
glomerular findings in paper I fit nicely with the description of glomerular damage 
caused by overload in Hostetter and Brenner’s milestone paper.13 The overload in old 
SHR, the increased glomerular pressure in the JMC, is a consequence of systemic 
hypertension and loss of autoregulation. Afferent arterioles in JMC originate either 
from the initial parts of the interlobular arteries, where the autoregulatory capacity of 
the interlobular arteries still is limited,72 or directly from the arcuate arteries.73, 74 
These arterioles are therefore particularly exposed to increased arterial pressure. 
Chronically elevated arterial pressure impairs autoregulation,75 and the glomerular 
capillary pressure rises. Moreover, the buffering of pressure variations is impaired in 
the JMC.76 Increased glomerular pressure is associated with glomerular hypertrophy 
(paper III) and leads at first to adaptive podocyte hypertrophy and then to maladaptive 
changes4 such as pseudocyst formation and footprocess effacement. Podocytes might 
even detach from the basement membrane and can be detected in the urine.77 
Podocytes form the smallest pores of the glomerular filtration barrier, the filtration 
slits with the diaphragm, and contribute with their negative charges to its charge 
selectivity. It is conceivable that podocyte damage and even more podocyte loss will 
have an impact on the filtration barrier. This is easily verified by the amount of 
albuminuria and proteinuria in old SHR. Two findings in paper I support that the 
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filtration defect indeed is localised to the juxtamedullary glomeruli. Firstly, increased 
filtration of the anionic peptide chymotrypsinogen is only found in the JMC of SHR. 
Secondly, podocytes with absorption droplets are predominantly present in the JMC. 
Absorption droplets are reabsorbed proteins that leak through the glomerular filter.7, 9  
6.2 Fibrosis in the JMC of SHR 
The common final pathway in renal disease progression encompasses not only 
segmental glomerulosclerosis but also tubular atrophy and interstitial fibrosis. Both 
are found together with the glomerular changes in the JMC of SHR.  
Collagen fibers are the hallmark of fibrosis.  Fibrous collagen can be visualised in 
histological sections by histochemical stains or by immunohistochemistry. Sirius Red 
specifically visualizes fibrillar collagens under polarised light and has been used 
widely for quantitative assessment of collagen content. It has been questioned 
whether the Sirius Red stain truly is quantitative.78 However, the amount of 
hydroxyprolin content compared with morphometry of Sirius Red stained sections 
revealed a highly significant correlation,79 indicating that Sirius Red stain combined 
with polarisation and automatic image analysis indeed is a solid tool for estimation of 
collagen content. The method shows excellent interobserver agreement.80  Lately, the 
clinical significance of the method has been doubted, because it has been shown in 
transplant kidney biopsies, that visual assessment of the fibrotic area was better 
correlated with serum creatinine and glomerular filtration rate (GFR) than Sirius Red 
using polarisation and image analysis.81 In this respect, it should be noted that visual 
assessment will interpret the entire interstitial area as fibrotic since it is done with low 
magnification for good overview. Interstitium as a whole is well correlated with 
serum creatinine and GFR; it consists not only of collagen but a multitude of proteins 
and tissue fluid, which as well might increase under pathological conditions. 
Therefore, the superior correlation of visual assessment with serum creatinine and 
GFR is not surprising. However, the result of visual assessment might be rather a 
parameter for interstitial area than a measure for fibrillar collagen. 
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In old SHR both GFR (paper I) and fibrillar collagen (paper II) are increased in the 
JMC.  Furthermore, it was shown that increased collagen deposition is not only a 
consequence of increased collagen production but also a consequence of disturbed 
metabolism (Paper II). 
6.3 Tubular atrophy is a consequence of inactivity 
The morphological hallmarks of the common final pathway – segmental 
glomerulosclerosis, tubular atrophy and interstitial fibrosis - are present in the JMC of 
SHR. However, their interrelation and the significance of vascular changes remained 
unclear. By means of morphology these questions could only be answered by 
visualising single nephrons and their supplying arterioles. Paper III investigated the 
matter by serial sectioning.  
It was shown that collapsed glomeruli without signs of segmental sclerosis were 
connected to atrophic tubules. These collapsed glomeruli were supplied by arterioles 
with significant media hypertrophy. The conclusion, drawn from these observations, 
is that nephrons in the JMC of SHR atrophy because of tubular inactivity, since 
glomerular blood flow and in consequence tubular urine flow were reduced by 
hypertrophy of afferent arterioles (Figure 13). 
This conclusion seems at first glance to be in contrast to some of our previous 
findings. Micropuncture studies in 70-week-old SHR showed increased mean 
glomerular pressure in the juxtamedullary glomeruli compared to WKY.63 Looking at 
the distribution of measured glomerular pressures in that previous study, all but one or 
two juxtamedullary SHR glomeruli had higher pressures than the WKY glomeruli, 
and no SHR glomerulus had a lower pressure than the lowest pressure of the WKY 
glomeruli. In contrast to this 4 of 28 glomeruli in 2 representative areas of the kidney 
cortex were collapsed (paper III), implying that there has to be a subset of glomeruli 
with reduced glomerular pressure.  
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Figure 13: Schematic diagram to show the morphologic changes in a degenerating nephron 
in the JMC of SHR compared to a normal nephron (right). The hypertrophied afferent 
arteriole is red, the glomerular convolute retracted and collapsed and tubular atrophy is 
indicated by thickened black lines. Not investigated parts of the nephron are depicted grey.  
 
The most probable reason that these glomeruli are not found by micropuncture is that 
the reduced perfusion makes them difficult to puncture and to identify by their 
pressure profile. Moreover, collapsed glomeruli show a thickened and multilayered 
Bowman’s capsule and the periglomerular tissue usually is inflamed and fibrotic, 
which might make them even harder to puncture. They might therefore have escaped 
the investigation procedure for glomerular intracapillary pressure. 
In addition, the rats in the previous investigation are 10 weeks older than the rats in 
paper III. The fraction of glomeruli with elevated intracapillary pressure might have 
increased in this time period along with the morphological signs of hypertensive renal 
damage, while insufficient perfusion of glomeruli might have become less important 
as cause for nephron loss.82 This explanation is supported by the fact, that glomeruli 
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with segmental sclerosis in the 60-week-old SHR were, unlike collapsed glomeruli, 
not a frequent finding. That segmental sclerosis increases in higher age is further 
supported by the fact that about 30% of juxtaglomerular glomeruli of the 80-week-old 
rats (paper I) showed adherences. An adhesion is considered the focus where 
segmental sclerosis starts.4 
Our initial assumption was that tubular atrophy is linked to segmental sclerosis, either 
by reduction of the blood supply to the tubulointerstitial compartment leading to 
hypoxia, or by misdirected filtration towards and along the Bowman’s capsule and 
along the proximal tubule. 
If the misfiltration hypothesis were true, then segmental sclerosis and tubular atrophy 
would have to be present in the same nephron.17 Since glomeruli with segmental 
sclerosis were not connected to atrophic tubules, this hypothesis has to be rejected for 
this stage of renal disease progression in SHR. Apart from that, the misfiltration 
hypothesis and our findings of tubular atrophy because of reduced tubular flow are 
not mutually exclusive. It is conceivable, that a misdirected filtrate, which spreads 
along the Bowman’s capsule to the tubular outlet and the initial parts of the proximal 
tubule, might expand and then compress the tubular orifice, thus stopping tubular 
flow. Some of the illustrations in related publications are consistent with this 
mechanism.15, 83 
That tubular atrophy and glomerular damage were confined to the same nephron, and 
that nephrons with tubular atrophy were found in close proximity to preserved 
nephrons, argues strongly against the hypoxia hypothesis. If the assumption is true 
that reduced glomerular outflow causes tubular atrophy because of reduced oxygen 
supply, zonal atrophy affecting several nephrons in close proximity has to be 
expected.16 In agreement with our observation, a recent in vivo study in 2K1C rats 
provided further evidence that hypoxia is not the cause of tubular atrophy when the 
blood flow is chronically reduced. Despite significant reduction of renal blood flow, 
the renal oxygen content in the clipped kidney did not diminish but rather showed a 
tendency to increase during the study period of 28 days.84 
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Our study was not designed to test the proteinuria hypothesis specifically.  However, 
there are observations arguing against proteinuria as cause of tubular atrophy. That 
absorption droplets in podocytes identify nephrons that leak protein, is supported by 
two observations in our studies. Firstly, there is a close correlation between 
percentage of glomeruli with absorption droplets in podocytes and amount of 
proteinuria (paper V). Secondly, glomeruli with absorption droplets were found in the 
JMC in SHR (paper I), where proteinuria in SHR originates.85 Serial sections in SHR 
showed that 8 of altogether 64 nephrons contained glomeruli with absorption droplets 
in podocytes, and these glomeruli were connected to normal tubules. Vice versa, 13 
nephrons showed atrophic tubules and none of the parent glomeruli did contain 
podocytes with absorption droplets (unpublished observation, Sabine Leh). In 60-
week-old SHR, there was thus morphologically no evidence that nephrons with 
proteinuria develop tubular atrophy. 
6.4 Tubular atrophy because of inactivity might be a 
universal principle 
Inactivity is a well known cause for atrophy.86 Reduced flow is equivalent to reduced 
activity, and tubular atrophy because of inactivity may be a mechanism in renal 
disease progression. At the pre-tubular level, flow can be reduced by hypoperfusion, 
as we argue in the SHR, by damage to the glomerular filter or by obstruction of the 
tubular outlet. There are several examples of how tubular flow might be reduced in 
other models of kidney disease, and where this is directly connected to tubular 
atrophy. 
In a rat model of puromycin nephrosis, a subset of glomeruli was small and connected 
to atrophic tubules 10 weeks after induction.87 Impairment of the glomerular filter by 
reduced filtration coefficient might have contributed to the tubular degeneration.88 
Both mechanisms – hypoperfusion and obstruction of the tubular outlet – have been 
described in a rat model of mesangioproliferative glomerulonephritis with crescents.89 
Two subsets of glomeruli were connected to atrophic or degenerating tubules: a 
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subset of small glomeruli with collapse of the capillary convolute and another subset 
of glomeruli with crescents that covered the tubular orifice. The pathogenetic 
mechanism of atrophy by obstruction of the tubular outlet has also been shown in a 
study of murine anti-GBM GN. In that study only nephrons with glomerular crescents 
obstructing the tubular outlet showed tubular degeneration.90  
In a study of uninephrectomy in rats treated with desoxycorticosterone-
trimethylacetate to produce hypertension, there was a subset of small shrunken 
glomeruli supplied by afferent arterioles with obstructive lesions,5 a finding that 
corresponds to our findings in paper III.  
A morphological study of tubular and glomerular pathology in subtotal nephrectomy91 
presented a number of observations that fit well with the concept of reduced tubular 
flow as reason for tubular atrophy. The degree of segmental sclerosis in individual 
glomeruli was well correlated with the degree of atrophy of the corresponding 
tubules, which is compatible with reduced single nephron GFR as the link between 
glomerular and tubular changes. Moreover, the volumes of glomeruli connected to 
atrophic tubules were significantly lower compared to glomeruli connected to normal 
tubules, an observation compatible with reduced glomerular perfusion and subsequent 
reduced tubular flow. 
We have argued that reduced tubular flow induces tubular atrophy in 60-week-old 
SHR, and that this mechanism may be common in renal disease progression in a 
variety of renal diseases. This raised the question how reduced tubular flow could be 
visualised in histological sections.  
Tubular cells contain primary cilia,92 which act as mechanosensors for tubular flow.93-
95
 Ciliary function has been widely studied in developmental diseases of mutated 
proteins connected to cilia, so called ciliopathies.96 Inversin is a ciliary protein, whose 
mutation causes nephronophtisis type 2.97 Inversin might be present in different 
subcellular localisations.98, 99 It has been shown that bending of cilia by flow increases 
inversin positivity.100  In SHR, degenerating tubules still have cilia, but compared to 
preserved tubules, they do not show apical cytoplasmic and nuclear positivity for 
inversin. We assume that absent inversin positivity is caused by reduced bending of 
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cilia due to reduced flow (paper III). Changes in length and number of tubular cilia 
have been shown in studies of acute renal failure, reperfusion injury and unilateral 
ureteral obstruction,101-103 but the function of cilia in acute and chronic kidney 
diseases is largely unknown. It can be deduced from studies in developmental 
diseases that cilia, by mechanosensation, may play an important role in regulation of 
epithelial cell differentiation. Further studies are needed to learn more about the role 
of ciliary signalling in the development of chronic kidney disease. 
6.5 TTA in 2K1C 
The main result in paper IV was the favourable effect of TTA on hypertension and 
hypertension induced renal damage. Even if the cause of hypertension is different in 
SHR and 2K1C, the pathogenetic mechanism of renal disease progression might be 
largely the same. As in SHR, morphological damage is more prominent in the JMC.104 
Arteries and arterioles show wall hypertrophy, endothelial cell proliferation and 
fibrinoid wall necrosis. It is conceivable that both glomerular hypoperfusion due to 
lumen obstruction and hyperperfusion due to loss of autoregulation might ensue. 
Hyperperfusion changes are well documented (paper IV). Whether there is a subset of 
glomeruli with collapsed capillary convolute, remains to be investigated. 
The pressure lowering effect of TTA in 2K1C hypertension is attributed primarily to 
its interference with the renin angiotensin system, as renin production in the clipped 
kidney as well as plasma renin activity are reduced, and as there is a strong tendency 
to reduce the plasma angiotensin II level (paper IV).  
6.6 Candesartan and pirfenidone in anti-GBM GN 
The rat model of anti-GBM GN used in paper V is in its acute phase characterised by 
glomerular basement defects with development of crescents.105 In the acute phase, 
obliteration of the tubular outlet by crescents might have been an important 
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mechanism of tubular degeneration.89, 90 Eight weeks after induction of 
glomerulonephritis, segmental glomerulosclerosis associated with absorption droplets 
and pseudocysts prevail, indicative of hyperperfusion damage (paper V).  
The renoprotective effect of candesartan in anti-GBM GN is probably based on 
inhibition of acute glomerular injury,106 as well as preventing chronic glomerular 
injury mainly by reduction of the intraglomerular pressure.22, 107 The former will 
preserve tubular flow, the latter will reduce glomerular overload.  
Candesartan does not reduce glomerular and tubulointerstitial changes to the level of 
the control group. This opens for a combination with other drugs with a different 
mechanism of action. The antifibrotic effect of pirfenidone is documented in many 
animal studies108, and confirmed in our study by reduction of mRNA expression of 
col1a1, and further supported by decrease of tubular degeneration and interstitial 
inflammation (paper V). Interestingly, pirfenidone also reduced proteinuria and the 
percentage of glomeruli with absorption droplets in podocytes. The beneficial effect 
on proteinuria was confirmed in some45, 51, 109 but not all47, 110, 111 studies in mouse and 
rat models of renal disease. In our study pirfenidone seemed to prevent glomerular 
damage and in consequence preserve tubular flow and inhibit tubular damage. As 
reactive oxygen species play a role in the early phase of anti-GBM GN,112 prevention 
of glomerular damage could be ascribed to the antioxidative properties of 
pirfenidone.34, 51, 113-115 Nitrotyrosine is an end product of peroxynitrite formation by 
nitric oxide and superoxide, and considered a marker of oxidative stress.116 
Nitrotyrosine positivity in tubules point to oxidative injury in these structures, and 
even if pirfenidone alone only numerically but not significantly decreased 
nitrotyrosine positivity, the significant favourable effect of combination therapy might 
have been achieved at least in part by the antioxidative properties of pirfenidone 
(paper V). That glomeruli did not show nitrotyrosine positivity at the end of the study, 
does not argue against oxidative stress in the acute phase of the disease but merely 
reflects the fact, that oxidative stress may be less important in the chronic phase. 
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6.7 The novel drugs TTA and pirfenidone in clinical studies 
What do we know about the effect of TTA and pirfenidone in clinical studies of 
chronic renal disease? 
There are no ongoing clinical trials for TTA in chronic renal disease. TTA changed 
the lipid profile and decreased the plasma concentration of free fatty acids in a phase 
II clinical trial for diabetes mellitus type II.117 The drug was also tested in a pilot 
study in 8 patients with psoriasis without significant effect.118 
Pirfenidone has been studied predominantly in fibrotic lung diseases, both in phase II 
and phase III trials119-123 with overall beneficial effect on tested parameters. There are 
also a couple of phase II studies in other organ systems with fibrotic diseases,124-130 in 
which pirfenidone showed either no or an uncertain effect. Studies of pirfenidone in 
chronic renal diseases are sparse. Pirfenidone has been tested in a clinical phase II 
trial in FSGS.131 Treatment improved glomerular filtration rate. However, blood 
pressure and proteinuria remained unchanged. A phase III trial in diabetic 
nephropathy132 showed a significant improvement of glomerular filtration rate 
compared to the placebo group. Another phase II trial in FSGS is ongoing.133 
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7. Conclusions 
60-week-old SHR show hypertensive glomerular damage, tubular atrophy, and 
interstitial fibrosis predominantly in the JMC. 
Interstitial fibrosis is the result of a disturbed collagen metabolism due to an increase 
of collagen production as well as an imbalance of collagen digestion and inhibition of 
digestion.  
Tubular atrophy is only found in nephrons with collapsed glomeruli and 
hypertrophied afferent arterioles, indicating that reduced glomerular and subsequent 
tubular flow induce tubular atrophy. The misdirected filtration hypothesis and the 
hypoxia hypothesis are not supported by our findings in 60-week-old SHR. 
The hypothesis that tubular atrophy is due to reduced tubular flow has to be evaluated 
in other rat models of chronic renal disease. The function of tubular cilia and its 
significance in renal disease should be further investigated. 
TTA decreases blood pressure and largely prevents damage in 2K1C hypertension 
mainly by interference with the renin angiotensin system.  
Pirfenidone ameliorates glomerular and tubulointerstitial damage in chronic anti-
GBM GN. Its effect is comparable to candesartan, however with a trend to slightly 
better results with candesartan treatment. Our results suggest an additive effect of 
combination treatment. 
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8. Errata 
Paper I 
Page 1087, first paragraph: The sentence “The  aChym of ~0.85 was similar in all 
cortical zones in SHR (P = 0.36), and the ratio of  aChym to  aChym was increased 
from …” should read: The  Chym of ~0.85 was similar in all cortical zones in SHR 
(P = 0.36), and the ratio of  aChym to  Chym was increased from …” 
“Adsorption droplets” in paper I, IV and V should read “absorption droplets”. 
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